View Exam | PowerPak

1. Which of the following is an appropriate indication for insulin replacement therapy?

A. An individual in hyperglycemic crisis (e.g., diabetic ketoacidosis) B. A person with a hemoglobin A1c greater than 9.0% who is symptomatic C. A hospitalized individual receiving enteral nutrition D. All of the above

2. According to the American Diabetes Association recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second-line add-on therapy to background metformin when compared to other drug classes?

A. The addition of basal insulin has the highest level of efficacy B. The addition of basal insulin has the lowest risk of hypoglycemia C. The addition of basal insulin has a neutral effect on weight D. None of the above

3. All of the following are key patient barriers to the use of insulin therapy EXCEPT:

A. Fear of injections B. Fear of weight gain C. Fear of hyperglycemia D. Fear of a loss of independence

4. All of the following are appropriate strategies to overcoming key barriers to insulin therapy, EXCEPT:

A. Avoid using insulin as a “threat” B. Use insulin pens and regimens that offer maximum regimen flexibility C. Give an injection in the office or clinic to dispel injection fears D. Wait to use insulin until all other treatment approaches have failed

5. Which of the following basal insulin products is considered an “ultra-long-acting” basal insulin?

A. Insulin degludec B. U-100 insulin glargine C. Insulin detemir D. NPH insulin

6. All of the following statements about the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec are true, EXCEPT:

A. These concentrated insulins are only available in pre-filled pens to minimize the risk of dosing errors B. Due to their longer duration of action, these concentrated insulins are associated with higher rates of hypoglycemia than U-100 insulin glargine C. These concentrated insulin products allow for a smaller volume of insulin injection than U-100 insulin products D. When administering a dose of insulin with concentrated insulins, the dose is simply dialed on the insulin pen (i.e., no dose conversion is needed)

7. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what is the recommended starting dose if she is switched to U-300 insulin glargine?

A. 8 units of U-300 insulin glargine B. 10 units of U-300 insulin glargine C. 12 units of U-300 insulin glargine D. 11 units of U-300 insulin glargine

8. Which of the following basal insulins is formulated in an acidic solution and, when injected, forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

A. Insulin detemir B. Insulin degludec C. Insulin glargine D. Insulin glulisine

9. TG is a 65-year-old man with type 2 diabetes. He weighs 100 kg. According to the American Diabetes Association recommendations for the initiation of basal insulin, which of the following options is an appropriate starting dose of basal insulin?

A. 10 units per day B. 5 units per day C. 20 units per day D. Both A and C would be appropriate options

10. After starting TG on 10 units of insulin daily, which of the following would be an appropriate plan for titrating his basal insulin therapy according to the American Diabetes Association standards of care?

A. Instruct TG to monitor his morning fasting blood glucose (FBG) and adjust his basal insulin dose to reach his FBG target B. Instruct TG to monitor his postprandial glucose (PPG) and adjust his basal insulin dose to reach his PPG target C. Tell TG his insulin dose will be assessed when he is back in the office in 3 months D. All of the above

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an appropriate indication for insulin replacement therapy?

2. According to the American Diabetes Association recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second-line add-on therapy to background metformin when compared to other drug classes?

3. All of the following are key patient barriers to the use of insulin therapy EXCEPT:

4. All of the following are appropriate strategies to overcoming key barriers to insulin therapy, EXCEPT:

5. Which of the following basal insulin products is considered an “ultra-long-acting” basal insulin?

6. All of the following statements about the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec are true, EXCEPT:

7. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what is the recommended starting dose if she is switched to U-300 insulin glargine?

8. Which of the following basal insulins is formulated in an acidic solution and, when injected, forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

9. TG is a 65-year-old man with type 2 diabetes. He weighs 100 kg. According to the American Diabetes Association recommendations for the initiation of basal insulin, which of the following options is an appropriate starting dose of basal insulin?

10. After starting TG on 10 units of insulin daily, which of the following would be an appropriate plan for titrating his basal insulin therapy according to the American Diabetes Association standards of care?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an appropriate indication for insulin replacement therapy?

2. According to the American Diabetes Association recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second-line add-on therapy to background metformin when compared to other drug classes?

3. All of the following are key patient barriers to the use of insulin therapy EXCEPT:

4. All of the following are appropriate strategies to overcoming key barriers to insulin therapy, EXCEPT:

5. Which of the following basal insulin products is considered an “ultra-long-acting” basal insulin?

6. All of the following statements about the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec are true, EXCEPT:

7. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what is the recommended starting dose if she is switched to U-300 insulin glargine?

8. Which of the following basal insulins is formulated in an acidic solution and, when injected, forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

9. TG is a 65-year-old man with type 2 diabetes. He weighs 100 kg. According to the American Diabetes Association recommendations for the initiation of basal insulin, which of the following options is an appropriate starting dose of basal insulin?

10. After starting TG on 10 units of insulin daily, which of the following would be an appropriate plan for titrating his basal insulin therapy according to the American Diabetes Association standards of care?

« Return to Activity

Customers who Purchased
this Activity also Purchased